Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 30, 2026 → Dec 30, 2026
See other at-risk trials from Dana-Farber Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Primary completion pushed from Oct 30, 2026 to Dec 30, 2026
    • Study completion pushed from Nov 30, 2026 to Apr 30, 2027
    • Start date changed from estimate of Aug 2026 to Sep 18, 2026
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  2. Start date: May 2026 to Aug 2026
    • Primary completion pushed from Jul 30, 2026 to Oct 30, 2026
    • Study completion pushed from Aug 30, 2026 to Nov 30, 2026
    v7
  3. Start date: Jan 2026 to May 2026
    • Primary completion date: Mar 30, 2026 to Jul 30, 2026
    • Study completion date: Mar 30, 2026 to Aug 30, 2026
    v6
  4. Start date: Jun 2025 to Jan 2026
    • Primary completion date: Nov 30, 2025 to Mar 30, 2026
    • Study completion date: Dec 30, 2025 to Mar 30, 2026
    v5
  5. Primary completion date: Mar 30, 2025 to Nov 30, 2025
    • Start date: Dec 2024 to Jun 2025
    • Study completion date: May 30, 2025 to Dec 30, 2025
    • Collaborators shortened, about 7 words
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Sep 30, 2024 to Mar 30, 2025
    • Start date: Aug 2024 to Dec 2024
    • Study completion date: Apr 30, 2025 to May 30, 2025
    v3
  2. Start date: Mar 2024 to Aug 2024v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
Trial Details
NCT Number NCT06117709
Lead Sponsor Dana-Farber Cancer Institute
Conditions
(from sponsor)		 Advanced Cancer, Pain
Related terms Agnosia, Pain
Enrollment 73 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov